Skip to main content

Table 8 Evidence of BTK inhibitors in patients with MZL

From: Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies

Patients type

BTK inhibitor regimens

Efficacy

Study

Phase

N

Patients with R/R MZL

Zanubrutinib

ORR: 68.2%; CR rate: 25.8%; median PFS: NR

MAGNOLIA [126]

2

68

Acalabrutinib

ORR: 53%; CR rate: 13%; median PFS: 27.4 months

ACE-LY-003 [127]

1/2

43

Ibrutinib

ORR: 58%; CR rate: 10%; median PFS: 15.7 months

PCYC-1121 [128]

2

63

  1. BTK, Bruton tyrosine kinase; CR, complete response; R/R, relapsed/refractory; MZL, marginal zone B-cell lymphoma; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; R/R, relapsed/refractory
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us